In Wake of 340B Contract Pharmacy Restrictions, Biosimilars Deserve Consideration

SPONSORED CONTENT

Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings and hopes for the best, the exclusions are harming patients’ ability to access

Read More »

Our Top 10 Breaking News Stories of 2022

Top 10
A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.

A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.

Number two on the list (based on how often a

Read More »

For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm

MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer's drug Aduhelm than it normally would for a Part B drug.

Medicare likely would pay 340B hospitals 106% of the average sales price (ASP) for Aduhelm—Biogen’s high-cost biologic drug for early-stage Alzheimer’s disease—for the first two or three years it is on the market, not the ASP minus 22.5%

Read More »

340B Covered Entities: Are You Ready for the Changes to Gilead’s Advancing Access Program?

SPONSORED CONTENT

This strategy could save the 340B proceeds at your organization

Today, underinsured or uninsured patients who are undergoing treatment with a Gilead HIV treatment or preventative medication may be eligible to receive those medications at no cost through Gilead’s Advancing Access program. Under this program, covered entities are able to receive full 340B proceeds from these dispenses and can use these funds

Read More »

U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case

The Supreme Court’s decision to hear the case over Medicare-related 340B cuts to hospitals surprised many observers. Oral arguments are scheduled for Nov. 30, with a decision not likely until the spring.

The U.S. Supreme Court has announced the cases it will take up this fall and 340B will be on the plate. The court recently posted its hearings schedule for the months of October through December and will

Read More »

House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill

House Republican conference chair Elise Stefanik (R-NY) is the most high profile sponsor of date for the bipartisan 340B Protect Act.

U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers

Read More »

HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position

HRSA and its 340B government contractor are looking to fill two critically important positions including replacing Rear Admiral Krista Pedley who has recently been promoted from her position as OPA Director.

The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program.

Read More »

“The Biggest Crisis Since 340B’s Inception:” 340B Report Leader Provides Input in New Podcast

In a new podcast, 340B Report Publisher and CEO Ted Slafsky provides input on key 340B challenges as well as some predictions.

The dispute with pharmaceutical firms over the use of contract pharmacies for 340B covered entities is the biggest crisis facing the program since its inception in the early 1990s, 340B Report Publisher and CEO Ted Slafsky tells “The

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report